Lecanemab: Shaping the Present and Future of Alzheimer’s Disease Treatment in Korea

Sung Hoon Kang

doi:10.17340/jkna.2025.0026

J Korean Neurol Assoc > Volume 43(3); 2025 > Article

레카네맙: 국내 알츠하이머병 치료의 현재와 미래

Neurology Education Section

Podcast

J Korean Neurol Assoc 2025; 43(3): 194-195.

Published online: August 1, 2025

DOI: https://doi.org/10.17340/jkna.2025.0026

레카네맙: 국내 알츠하이머병 치료의 현재와 미래

강성훈

고려대학교 의과대학 고려대학교구로병원 신경과

Lecanemab: Shaping the Present and Future of Alzheimer’s Disease Treatment in Korea

Sung Hoon Kang, MD

Department of Neurology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea

Address for correspondence Sung Hoon Kang, MD Department of Neurology, Korea University Guro Hospital, Korea University College of Medicine, 148 Gurodong-ro, Guro-gu, Seoul 08308, Korea Tel: +82-2-2626-1250 Fax: +82-2-2626-1256 E-mail: shkang85@naver.com

Received June 20, 2025 Revised July 1, 2025 Accepted July 1, 2025

This is an Open Access journal distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted, distribution, and reproduction in any medium, provided the original work is properly cited.

[연관 대한신경과학회지 발표 문헌] DOI: https://doi.org/10.17340/jkna.2021.3.4

Professor Sung Hoon Kang

Audio. Lecanemab: shaping the present and future of Alzheimer’s disease treatment in Korea.

The Alzheimer’s disease treatment lecanemab has garnered significant attention as a groundbreaking therapy since its introduction in Korea in late 2024, due to its ability to intervene in the core amyloid pathology of the disease and slow its progression [1,2]. In this interview, we are joined by Professor Sung Hoon Kang, a dementia specialist at Korea University Guro Hospital, who has extensive clinical experience with lecanemab in real-world Alzheimer’s disease cases. We discuss the drug’s mechanism of action, indications, administration and monitoring strategies, as well as actual patient cases [3-5].

REFERENCES

1. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer's disease. N Engl J Med 2023;388:9-21.

2. Chen C, Katayama S, Lee JH, Lee JY, Nakagawa M, Torii K, et al. Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease. J Prev Alzheimers Dis 2025;12:100160.

3. Park KH, Kim GH, Kim CH, Koh SH, Moon SY, Park YH, et al. Lecanemab: appropriate use recommendations by Korean Dementia Association. Dement Neurocogn Disord 2024;23:165-187.

4. Kang SH, Jeong JH, Pyun JM, Kim GH, Park YH, Shim Y, et al. Eligibility for lecanemab treatment in the Republic of Korea: real-world data from memory clinics. J Clin Neurol 2025;21:182-189.

5. Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, et al. Diagnostic accuracy of a plasma phosphorylated Tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol 2024;81:255-263.

TOOLS

METRICS

0 Crossref
0 Scopus
1,475 View
68 Download

Related articles

Asymmetric Amyloid-β Burden and Neurodegeneration in Late-Onset Alzheimer’s Disease Dementia2021 August;39(3)

Logopenic Progressive Aphasia Revealing Positive Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease2014 ;32(2)

Typical Case of Alzheimer’s Disease Confirmed by Autopsy2013 ;31(1)

Eating Seizures in a Patient With Alzheimer’s Disease2010 ;28(4)

Quantitative EEG findings in different stage of Alzheimer’s Disease2005 ;23(3)

Editorial Office: (ZIP 03163) #1111, Daeil Bldg, 12, Insadong-gil, Jongno-gu, Seoul, Korea
Tel: +82-2-737-6530 Fax: +82-2-737-6531 E-mail: jkna@neuro.or.kr